wegovy

Editor’s Note: This story has been updated to include a statement from a Novo Nordisk spokesperson. Sen. Bernie Sanders (I-Vt.) has once again criticized Novo Nordisk A/S (NYSE:NVO) for the high price of its diabetes drug, Ozempic, in the United States. What Happened: On Sunday, Sanders took...

Researchers are now suggesting that a drug for Type 2 diabetes and obesity might actually have anti-aging powers. Harlan Krumholz of the Yale School of Medicine declared that semaglutide, marketed as Ozempic, could be a game-changer with benefits far beyond our wildest dreams after several...

The rivalry between Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments. Novo Nordisk & Eli Lilly – Expanding Beyond...

Shares of the weight-loss giant Novo Nordisk A/S (NYSE:NVO) are plunging by over 6% during Wednesday morning trading in New York, in response to the quarterly results released during the premarket. What Happened: Novo Nordisk reported second-quarter 2024 sales of DKK 68.06 billion ($9.972 billion...

Novo Nordisk A/S (NYSE:NVO) has reported that U.S. patients are staying on their Wegovy weight-loss medication for an average of six months. What Happened: Doug Langa, Novo’s head of North America operations, shared this information during a call with analysts following the company’s...

Shares of Novo Nordisk (NYSE:NVO), the pharmaceutical giant behind “miracle” weightloss drugs Ozempic and Wegovy, took a hit in pre-market trading on Wednesday, following the announcement of its second-quarter results, which fell short of expectations. The company also revised its...

In Wednesday’s pre-market trading, shares of Novo Nordisk A/S (NYSE:NVO) are witnessing a fall after the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for Novo Nordisk’s semaglutide, Wegovy, to reduce the risk of heart complications or...

GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy. Shares of Eli Lilly plummeted...

Novo Nordisk A/S. (NYSE:NVO) has found that its “miracle” weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues. What Happened: A study conducted at the University of Oxford revealed that patients who used...

The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga. “Our view is that in the long term, this is not a two-horse race...

In a recent tweet, Bernie Sanders (I-Vt.) criticized the pricing of a popular diabetes drug, Ozempic, and its manufacturer, Novo Nordisk A/S (NYSE:NVO). What Happened: Sanders took to X, formerly Twitter, on Wednesday to express his concerns about the pricing of Ozempic. He suggested that the drug...

On Tuesday, U.S. stocks showed mixed results. The Dow Jones Industrial Average closed down by nearly 0.8%, finishing at 39,112.16. The S&P 500 rose by almost 0.4% to end the regular session at 5,469.30, while the Nasdaq climbed nearly 1.3% to close at 17,717.65. These are the top stocks that...

Novo Nordisk‘s (NYSE:NVO) weight loss drug Wegovy has received approval in China, representing a notable achievement for the Danish pharmaceutical firm. In response to this announcement, the company’s U.S.-listed stock is experiencing a surge of over 2% in pre-market trading on Tuesday...

Novo Nordisk A/S (NYSE:NVO) is set to invest $4.1 billion in expanding its U.S. manufacturing operations to meet the increasing demand for its weight loss drugs. What Happened: The Danish pharmaceutical company plans to build a new 1.4 million square foot manufacturing plant near Raleigh, North...

Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity medication, Wegovy, has been shown to cause more weight loss in women with prevalent heart disease than in men with the same condition. What Happened: In a recent analysis of study data, involving 1,145 patients, centered on a condition known as...